Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
1998 8
1999 41
2000 65
2001 144
2002 265
2003 328
2004 482
2005 576
2006 621
2007 727
2008 725
2009 769
2010 760
2011 765
2012 824
2013 846
2014 905
2015 864
2016 926
2017 922
2018 886
2019 922
2020 1018
2021 1059
2022 898
2023 854
2024 235

Text availability

Article attribute

Article type

Publication date

Search Results

15,276 results

Results by year

Filters applied: . Clear all
Page 1
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group. Colombel JF, et al. N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492. N Engl J Med. 2010. PMID: 20393175 Free article. Clinical Trial.
BACKGROUND: The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown. ...Serious infections developed in 3.9% of patients in the combination-therapy group, 4.9% of those in the infliximab grou …
BACKGROUND: The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease ar …
Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis.
Sakkat A, Cox G, Khalidi N, Larche M, Beattie K, Renzoni EA, Morar N, Kouranos V, Kolb M, Hambly N. Sakkat A, et al. Respir Res. 2022 Mar 9;23(1):54. doi: 10.1186/s12931-022-01971-5. Respir Res. 2022. PMID: 35264154 Free PMC article. Clinical Trial.
Our study aimed to investigate the effectiveness of infliximab in patients with refractory sarcoidosis. METHODS: Sarcoidosis patients from three tertiary centres were retrospectively identified by pharmacy records based on treatment with infliximab. ...Relapse is co …
Our study aimed to investigate the effectiveness of infliximab in patients with refractory sarcoidosis. METHODS: Sarcoidosis patients …
PF-06438179/GP1111: An Infliximab Biosimilar.
Al-Salama ZT. Al-Salama ZT. BioDrugs. 2018 Dec;32(6):639-642. doi: 10.1007/s40259-018-0310-5. BioDrugs. 2018. PMID: 30284704 Free PMC article. Review.
The tolerability, immunogenicity and safety profiles of GP1111 were similar to those of reference infliximab, and switching from reference infliximab to GP1111 had no impact on safety, efficacy or immunogenicity. The role of reference infliximab in the manage …
The tolerability, immunogenicity and safety profiles of GP1111 were similar to those of reference infliximab, and switching from refe …
SB2: An Infliximab Biosimilar.
Lamb YN, Scott LJ, Deeks ED. Lamb YN, et al. BioDrugs. 2017 Oct;31(5):461-464. doi: 10.1007/s40259-017-0240-7. BioDrugs. 2017. PMID: 28803431 Review.
SB2 was generally well tolerated; the safety and immunogenicity profiles were similar to those of reference infliximab with no additional safety concerns identified. Switching from reference infliximab to SB2 did not impact clinical efficacy, safety or immunogenicit …
SB2 was generally well tolerated; the safety and immunogenicity profiles were similar to those of reference infliximab with no additi …
Immunogenicity of infliximab and adalimumab.
Murdaca G, Negrini S, Greco M, Schiavi C, Giusti F, Borro M, Puppo F. Murdaca G, et al. Expert Opin Drug Saf. 2019 May;18(5):343-345. doi: 10.1080/14740338.2019.1602117. Epub 2019 Apr 16. Expert Opin Drug Saf. 2019. PMID: 30938213 No abstract available.
Therapeutic Drug Monitoring of Infliximab in Acute Severe Ulcerative Colitis.
Gordon BL, Battat R. Gordon BL, et al. J Clin Med. 2023 May 10;12(10):3378. doi: 10.3390/jcm12103378. J Clin Med. 2023. PMID: 37240484 Free PMC article. Review.
Steroid-refractory ASUC patients require salvage therapy with infliximab, cyclosporine, or colectomy. Fewer data are available for the use of TDM of infliximab in ASUC. The pharmacokinetics of ASUC make TDM in this population more complex. High inflammatory burden i …
Steroid-refractory ASUC patients require salvage therapy with infliximab, cyclosporine, or colectomy. Fewer data are available for th …
Remicade (infliximab).
Claussen DW. Claussen DW. Gastroenterol Nurs. 1998 Nov-Dec;21(6):256-9. doi: 10.1097/00001610-199811000-00008. Gastroenterol Nurs. 1998. PMID: 10095510 Review. No abstract available.
The Experience with Biosimilars of Infliximab in Rheumatic Diseases.
Azevedo VF, Kos IA, Ariello L. Azevedo VF, et al. Curr Pharm Des. 2017;23(44):6752-6758. doi: 10.2174/1381612824666171129192040. Curr Pharm Des. 2017. PMID: 29189135 Review.
BACKGROUND: Infliximab biosimilars are the first biosimilars of monoclonal antibodies approved by the main regulatory agencies. ...In addition, the European experience has proved the economic advantages of the incorporation of infliximab biosimilars in clinical prac …
BACKGROUND: Infliximab biosimilars are the first biosimilars of monoclonal antibodies approved by the main regulatory agencies. ...In …
Infliximab-associated Chiasmopathy.
Farrell E, Sacks JG. Farrell E, et al. Ochsner J. 2008 Fall;8(3):140-5. Ochsner J. 2008. PMID: 21603466 Free PMC article.
Optic neuropathy has been reported in association with the use of tumor necrosis factor-alpha antagonists such as etanercept, infliximab, and adalimumab. This is a report of a patient who began experiencing decreased vision approximately 1 month after starting inflixima
Optic neuropathy has been reported in association with the use of tumor necrosis factor-alpha antagonists such as etanercept, infliximab
Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.
Alten R, An Y, Kim DH, Yoon S, Peyrin-Biroulet L. Alten R, et al. Clin Drug Investig. 2022 Jun;42(6):477-489. doi: 10.1007/s40261-022-01162-6. Epub 2022 Jun 3. Clin Drug Investig. 2022. PMID: 35657560 Review.
Subcutaneous infliximab demonstrated an improved pharmacokinetic profile compared with intravenous infliximab: the more stable exposure and increased systemic drug concentrations mean it has been cited as a biobetter. ...Initial evidence is emerging with subcutaneou …
Subcutaneous infliximab demonstrated an improved pharmacokinetic profile compared with intravenous infliximab: the more stable …
15,276 results
You have reached the last available page of results. Please see the User Guide for more information.